| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 04/17/2002 | EP1196595A2 Methods of inducing cell death |
| 04/17/2002 | EP1196594A2 Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 coxsacki adenovirus receptor (car) |
| 04/17/2002 | EP1196591A1 Moraxella catarrhalis polypeptides |
| 04/17/2002 | EP1196587A2 Antigenic meningococcal peptides |
| 04/17/2002 | EP1196586A1 Basb111 polypeptide and polynucleotide from moraxella catharrhalis |
| 04/17/2002 | EP1196575A2 Gtp-binding protein associated factors |
| 04/17/2002 | EP1196574A2 Human proteins involved in detoxification |
| 04/17/2002 | EP1196570A2 Human polypeptides and methods for the use thereof |
| 04/17/2002 | EP1196562A1 Novel genes and their use in the modulation of obesity, diabetes and energy imbalance |
| 04/17/2002 | EP1196560A1 Neurotrophic factor receptor gfr-alpha-4 |
| 04/17/2002 | EP1196559A1 Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis |
| 04/17/2002 | EP1196544A2 Packaging systems for human recombinant adenovirus to be used in gene therapy |
| 04/17/2002 | EP1196441A1 Keratinocyte growth factor-2 |
| 04/17/2002 | EP1196435A1 Recombinant adenovirus |
| 04/17/2002 | EP1196426A1 Cytoplasmic transfer to de-differentiate recipient cells |
| 04/17/2002 | EP1196197A2 Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene |
| 04/17/2002 | EP1196196A2 Conjugate for mediating cell, compartment or membrane-specific transport of active substances |
| 04/17/2002 | EP1196145A1 Methods and apparatus for preparation of lipid vesicles |
| 04/17/2002 | EP0994726B1 Compositions suitable for delivery of genes to epithelial cells |
| 04/17/2002 | EP0986404B1 Gene therapy delivery system for targeting to endothelia |
| 04/17/2002 | EP0852627A4 Cell death protein |
| 04/17/2002 | EP0662827B1 Diagnostic methods and pharmaceutical compositions based on notch proteins and nucleic acids |
| 04/17/2002 | CN1345375A Streptococcus pneumoniae antigens |
| 04/17/2002 | CN1345374A HER-2/neu fusion proteins |
| 04/17/2002 | CN1345373A Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase |
| 04/17/2002 | CN1345329A Tumor mecrosis factor receptors 6 alpha and beta |
| 04/17/2002 | CN1345248A Gene therapeutics |
| 04/17/2002 | CN1345232A Hydrogel particle formulations |
| 04/17/2002 | CN1344566A Tumor vaccine constituting method by combining dendritic cell multiplication and chemotaxis factor and suicide gene |
| 04/16/2002 | US6372959 Expression vector of a mud loach growth hormone gene |
| 04/16/2002 | US6372957 Transgenic mouse comprising a MEF2 binding site operatively linked to an indicator gene and methods of use |
| 04/16/2002 | US6372722 Method for nucleic acid transfection of cells |
| 04/16/2002 | US6372720 Liposome fusion and delivery vehicle |
| 04/16/2002 | US6372714 O,o*-ditetradecanoyl-(a-trimethylammonioacetyl)diethanolamine halide, phosphatide and cholesterol |
| 04/16/2002 | US6372501 Glucose responsive β-cell line |
| 04/16/2002 | US6372500 For transfection of epithelial tissue with the cassettes in therapy of cystic fibrosis, emphysema, cancers of epithelial origin arising in the lung or other organs |
| 04/16/2002 | US6372499 Transfection efficiency |
| 04/16/2002 | US6372492 Antisense modulation of talin expression |
| 04/16/2002 | US6372490 Nucleic acid encoding the MDM interacting protein |
| 04/16/2002 | US6372489 For therapy of disorders related to tyrosinase gene expression and melanin biosynthesis |
| 04/16/2002 | US6372488 AMPA-binding human GluR4 receptors |
| 04/16/2002 | US6372487 Polynucleotides encoding peptide release factor, prfC (RF-3), a GTP-binding protein |
| 04/16/2002 | US6372473 Tissue plasminogen activator-like protease |
| 04/16/2002 | US6372471 Cloning and recombinant production of vespid venom enzymes, such as phospholipase and hyaluronidase, and immunological therapies based thereon |
| 04/16/2002 | US6372468 Useful in the development of human therapeutics and diagnostic formulations |
| 04/16/2002 | US6372454 Also vectors, host cells; screening methods for identifying agonists or antagonists of follistatin-3 activity; diagnostic methods for detecting reproductive system and cell differentiation disorders and treating these |
| 04/16/2002 | US6372441 Detecting the expression of the variable exon v10 in the cd44 gene in a patient or in a sample obtained from a patient, wherein the expression of the variable exon v10 in the cd44 gene indicates hodgkin's lymphomas |
| 04/16/2002 | US6372433 Antisense modulation of inhibitor of DNA binding-1 expression |
| 04/16/2002 | US6372250 Non-invasive gene targeting to the brain |
| 04/16/2002 | US6372208 Method of reducing an immune response to a recombinant virus |
| 04/16/2002 | US6372045 Apparatus for preparing sample cartridges for a particle acceleration device |
| 04/16/2002 | CA2217565C Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor (gdnf) protein product |
| 04/16/2002 | CA2046607C Inhibiting transformation of cells having elevated purine metabolic enzyme activity |
| 04/11/2002 | WO2002029403A1 Gata-3 expression inhibitor and method of screening the same |
| 04/11/2002 | WO2002029103A2 Gene expression profiles in liver cancer |
| 04/11/2002 | WO2002029088A2 Highly expressible genes |
| 04/11/2002 | WO2002029086A2 Nucleic acid sequences differentially expressed in cancer tissue |
| 04/11/2002 | WO2002029074A2 Genetic immunisation against cervical carcinoma |
| 04/11/2002 | WO2002029073A2 Gene delivery vectors for stem cells |
| 04/11/2002 | WO2002029072A2 Targetting molecules for adenoviral vectors |
| 04/11/2002 | WO2002029065A2 Retroviral vectors containing internal ribosomal entry sites |
| 04/11/2002 | WO2002029062A2 Cytokine proteins |
| 04/11/2002 | WO2002029058A2 Human proteins, polynucleotides encoding them and methods of using the same |
| 04/11/2002 | WO2002029056A2 Mini-dystrophin nucleic acid and peptide sequences |
| 04/11/2002 | WO2002029053A1 Novel g protein-coupled receptor protein and dna thereof |
| 04/11/2002 | WO2002029050A2 Regulation of human secretin receptor-like gpcr |
| 04/11/2002 | WO2002029047A2 Regulation of human gpcr-like protein |
| 04/11/2002 | WO2002029044A2 Modulation of the transcription of pro-inflammatory gene products |
| 04/11/2002 | WO2002029038A2 Novel proteins and nucleic acids encoding same and antibodies directed against these proteins |
| 04/11/2002 | WO2002029031A2 Isoprenoid-dependent ras anchorage (idra) proteins |
| 04/11/2002 | WO2002029026A2 Human proteases and polynucleotides encoding the same |
| 04/11/2002 | WO2002029011A2 Use of a composition with antioxidant activity for conditioning stem cells |
| 04/11/2002 | WO2002028997A2 Methods of isolating bipotent hepatic progenitor cells |
| 04/11/2002 | WO2002028906A2 Regulation of human sphingosine kinase-like protein |
| 04/11/2002 | WO2002028897A2 Human g-protein coupled receptor and uses thereof |
| 04/11/2002 | WO2002028891A2 Listeria inocua, genome and applications |
| 04/11/2002 | WO2002028878A1 Antisense modulation of smad6 expression |
| 04/11/2002 | WO2002028440A1 Methods and compositions for modulating t cell activation and uses thereof |
| 04/11/2002 | WO2002028439A2 Transferrin-polycation/dna complexes for the systemic treatment of tumour diseases using cytotoxic proteins |
| 04/11/2002 | WO2002028420A2 Regulation of cell proliferation and differentiation using topically applied nucleic acid molecules |
| 04/11/2002 | WO2002028418A1 Methods of modulating apoptosis by administration of relaxin agonists or antagonists |
| 04/11/2002 | WO2002028414A1 Compositions and methods for wt1 specific immunotherapy |
| 04/11/2002 | WO2002028406A2 Induction of blood vessel formation by polynucleotides encoding sphingosine kinases |
| 04/11/2002 | WO2002028371A1 Vaccine composition comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight |
| 04/11/2002 | WO2002028370A1 Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight |
| 04/11/2002 | WO2002028168A1 High efficiency regulatable gene expression system |
| 04/11/2002 | WO2002028165A2 Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| 04/11/2002 | WO2002000725A3 G-protein coupled receptor org10 |
| 04/11/2002 | WO2001092310A3 Regulation of human transketolase-like enzyme |
| 04/11/2002 | WO2001090391A3 Utilization of non-viral sequences for minus-strand dna transfer and gene reconstitution |
| 04/11/2002 | WO2001089559A3 Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine |
| 04/11/2002 | WO2001087342A3 Delivery devices for treatment of vascular disease |
| 04/11/2002 | WO2001085935A3 Endothelial differentiation gene 6-like g protein coupled receptor |
| 04/11/2002 | WO2001074856A3 Wnt-7b-like polypeptides and nucleic acids encoding same |
| 04/11/2002 | WO2001072780A3 Polynucleotides for diagnosing mammary gland cancer |
| 04/11/2002 | WO2001070989A3 Genetically modified plants and plant cells comprising heterologous heavy metal transport and complexation proteins |
| 04/11/2002 | WO2001070971A3 Regulation of human mas oncogene-related g protein-coupled receptor |
| 04/11/2002 | WO2001070814A3 Regulation of human rta-like g protein-coupled receptor |
| 04/11/2002 | WO2001068822A3 Method of treating phenylketonuria and means therefor |
| 04/11/2002 | WO2001066085A3 Micellar pharmaceutical compositions for buccal and pulmonary application |